Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$97.94

-1.53 (-1.54%)

, ONCE

Spark Therapeutics

$77.63

3.84 (5.20%)

09:10
08/07/18
08/07
09:10
08/07/18
09:10

BioMarin competitive positioning 'improved measurably,' says Piper Jaffray

Spark Therapeutics' (ONCE) update this morning for hemophilia A candidate SPK-8011 was disappointing both efficacy- and safety-wise, Piper Jaffray analyst Christopher Raymond tells investors in a research note titled "Spark Fails to Ignite; Valrox Competitive Positioning Just Improved Measurably." He believes the news "goes a long way" to putting this potential threat to BioMarin (BMRN) "to bed." The analyst is incrementally positive on BioMarin's competitive positioning in hemophilia A and keeps an Overweight rating on the shares with a $120 price target. The Spark data compares unfavorably to BioMarin's valrox, Raymond writes. He remains a buyer of BioMarin with an Overweight rating and $120 price target. The stock in premarket trading is up $5.55 to $103.50.

BMRN

BioMarin

$97.94

-1.53 (-1.54%)

ONCE

Spark Therapeutics

$77.63

3.84 (5.20%)

  • 07

    Aug

  • 07

    Aug

  • 10

    Sep

  • 12

    Sep

BMRN BioMarin
$97.94

-1.53 (-1.54%)

05/29/18
SBSH
05/29/18
NO CHANGE
Target $108
SBSH
Buy
BioMarin price target raised to $108 from $100 at Citi
Citi analyst Robyn Karnauskas raised her price target for Biomarin Pharmaceutical to $108 following the approval of Palynziq. The drug received a broad label and monitoring only for a single dose can accelerate patient uptake, Karnauskas tells investors in a research note. She keeps a Buy rating on BioMarin shares.
08/03/18
PIPR
08/03/18
NO CHANGE
Target $120
PIPR
Overweight
BioMarin price target raised to $120 from $114 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for BioMarin Pharmaceutical to $120 and keeps an Overweight rating on the name following the company's "solid" Q2 results. The analyst believes the Palynziq launch is going well and says BioMarin provided incrementally positive updates for hemophilia gene therapy candidate valrox. He sees a "credible chance" that BioMarin could file early for accelerated approval on valrox Phase 1 data. Raymond continues to like to setup for the stock and would be a buyer to levels approaching $120.
08/06/18
WEDB
08/06/18
NO CHANGE
Target $120
WEDB
Outperform
BioMarin price target raised to $120 from $115 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for BioMarin to $120 from $115 after the company reported "solid" Q2 results. The analyst reiterates an Outperform rating on the shares.
08/07/18
STFL
08/07/18
INITIATION
Target $114
STFL
Buy
BioMarin transferred with a Buy at Stifel
Stifel transferred coverage of BioMarin to analyst Paul Matteis, who set a Buy rating and $114 price target on the shares. He sees the approved product base having a path to about $2B in 2019 revenue, which provides a share floor of about $80 ahead of a handful of clinical catalysts during the next 12-18 months, Matteis tells investors. BioMarin is better positioned than most mature biotechs in terms of drug pricing pressure and competition risk, added the analyst.
ONCE Spark Therapeutics
$77.63

3.84 (5.20%)

07/16/18
CANT
07/16/18
NO CHANGE
Target $103
CANT
Overweight
Start of Pfizer trial encouraging for Spark Therapeutics, says Cantor Fitzgerald
After Spark Therapeutics (ONCE) announced that partner Pfizer (PFE) initiated a Phase 3 study to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in the usual care setting, Cantor Fitzgerald analyst Elemer Piros said he was encouraged that the program transfer is on track and he remains bullish on the fidanacogene elaparvovec program. He reiterates his Overweight rating and $103 price target on Spark shares.
07/19/18
RBCM
07/19/18
DOWNGRADE
RBCM
Sector Perform
Spark Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
07/19/18
RBCM
07/19/18
DOWNGRADE
Target $75
RBCM
Sector Perform
Spark Therapeutics cut to Sector Perform at RBC Capital on SPK-801 concern
As reported earlier, RBC Capital analyst Kennen MacKay downgraded Spark Therapeutics to Sector Perform from Outperform and kept his $75 price target. The analyst notes that after a strong run-up in the stock price driven by lofty expectations for the ongoing Phase 1/2 trial of SPK-8011 in patients with hemophilia, achieving mean FVIII expression levels of 30-55% anticipated by the Street could prove "challenging" as "data to date has not indicated clear dose responsiveness." McKay also cites the possibility of regulatory delays to gain approval for sale of Luxturna among the risks for Spark Therapeutics.
07/19/18
07/19/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Underperform from Hold at Needham with analyst Rajvindra Gill saying the stock remains overvalued in spite of its 16% decline from the the June 2017 peak. 2. Procter & Gamble (PG) downgraded to Neutral from Buy at UBS with analyst Steven Strycula saying the company's reinvestment cycle limits earnings and stock upside. 3. Terex (TEX) downgraded to Market Perform from Outperform at Wells Fargo with analyst Andrew Casey saying his crane check was good but not great, with demand appearing to sequentially flatten. 4. Spark Therapeutics (ONCE) downgraded to Sector Perform from Outperform at RBC Capital with analyst Kennen MacKay saying that after a strong run-up in the stock price driven by lofty expectations for the ongoing Phase 1/2 trial of SPK-8011 in patients with hemophilia, achieving mean FVIII expression levels of 30-55% anticipated by the Street could prove "challenging" as "data to date has not indicated clear dose responsiveness." 5. Hyatt (H) downgraded to Hold from Buy at Berenberg with analyst El Kassir saying Hyatt continues to benchmark well on its pipeline, however, there is little scope for future growth to accelerate from current levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

01:45
08/16/18
08/16
01:45
08/16/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

AVLR

Avalara

$34.68

-1.375 (-3.81%)

23:51
08/15/18
08/15
23:51
08/15/18
23:51
Upgrade
Avalara rating change at Goldman Sachs »

Avalara upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$70.61

-0.56 (-0.79%)

23:22
08/15/18
08/15
23:22
08/15/18
23:22
Hot Stocks
SK Telecom deploys Xilinx FPGAs for AI acceleration »

Xilinx jointly announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IVC

Invacare

$16.50

0.15 (0.92%)

21:30
08/15/18
08/15
21:30
08/15/18
21:30
Downgrade
Invacare rating change at KeyBanc »

Invacare downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

PRO

Pros Holdings

$35.39

-1.91 (-5.12%)

20:39
08/15/18
08/15
20:39
08/15/18
20:39
Syndicate
Pros Holdings 3.8M share Secondary priced at $34.00 »

It appears selling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 21

    Aug

  • 06

    Sep

  • 07

    Sep

  • 16

    Aug

IIN

IntriCon

$63.85

-4.9 (-7.13%)

20:34
08/15/18
08/15
20:34
08/15/18
20:34
Syndicate
IntriCon 1.5M share Secondary priced at $55.00 »

Stifel acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 16

    Aug

ADUS

Addus HomeCare

$59.35

-3.1 (-4.96%)

20:33
08/15/18
08/15
20:33
08/15/18
20:33
Syndicate
Addus HomeCare 2.1M share Secondary priced at $59.00 »

Jefferies, RBC Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

LABL

Multi-Color

$63.90

-1 (-1.54%)

20:32
08/15/18
08/15
20:32
08/15/18
20:32
Downgrade
Multi-Color rating change at KeyBanc »

Multi-Color downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$90.24

-0.565 (-0.62%)

, JCP

J.C. Penney

$2.40

-0.24 (-9.09%)

20:25
08/15/18
08/15
20:25
08/15/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

WMT

Walmart

$90.24

-0.565 (-0.62%)

JCP

J.C. Penney

$2.40

-0.24 (-9.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 16

    Aug

WUBA

58.com

$58.59

-3.27 (-5.29%)

19:09
08/15/18
08/15
19:09
08/15/18
19:09
Hot Stocks
Breaking Hot Stocks news story on 58.com »

58.com sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 10

    Sep

WUBA

58.com

$58.59

-3.27 (-5.29%)

19:08
08/15/18
08/15
19:08
08/15/18
19:08
Earnings
58.com reports Q2 adjusted earnings per ADS 82c, consensus 68c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 10

    Sep

WAIR

Wesco Aircraft

$13.65

-0.3 (-2.15%)

19:07
08/15/18
08/15
19:07
08/15/18
19:07
Initiation
Wesco Aircraft initiated at UBS »

Wesco Aircraft initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGI

Triumph Group

$21.10

-0.9 (-4.09%)

19:07
08/15/18
08/15
19:07
08/15/18
19:07
Initiation
Triumph Group initiated at UBS »

Triumph Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXL

Hexcel

$68.40

-1.13 (-1.63%)

19:06
08/15/18
08/15
19:06
08/15/18
19:06
Initiation
Hexcel initiated at UBS »

Hexcel initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ERJ

Embraer

$18.64

-0.495 (-2.59%)

19:05
08/15/18
08/15
19:05
08/15/18
19:05
Initiation
Embraer initiated at UBS »

Embraer initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CW

Curtiss-Wright

$130.92

-2.42 (-1.81%)

19:04
08/15/18
08/15
19:04
08/15/18
19:04
Initiation
Curtiss-Wright initiated at UBS »

Curtiss-Wright initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$208.08

-1.73 (-0.82%)

19:03
08/15/18
08/15
19:03
08/15/18
19:03
Initiation
L3 Technologies initiated at UBS »

L3 Technologies initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$192.29

-1.33 (-0.69%)

19:03
08/15/18
08/15
19:03
08/15/18
19:03
Initiation
General Dynamics initiated at UBS »

General Dynamics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDRBF

Bombardier

$0.00

(0.00%)

19:02
08/15/18
08/15
19:02
08/15/18
19:02
Initiation
Bombardier initiated at UBS »

Bombardier initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEI

Heico

$76.50

-1.81 (-2.31%)

19:00
08/15/18
08/15
19:00
08/15/18
19:00
Initiation
Heico initiated at UBS »

Heico initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 13

    Sep

  • 06

    Nov

HRS

Harris

$162.73

-2.15 (-1.30%)

18:59
08/15/18
08/15
18:59
08/15/18
18:59
Initiation
Harris initiated at UBS »

Harris initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$291.52

-2.35 (-0.80%)

18:59
08/15/18
08/15
18:59
08/15/18
18:59
Initiation
Northrop Grumman initiated at UBS »

Northrop Grumman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNC

PNC Financial

$142.03

-0.7 (-0.49%)

, WFC

Wells Fargo

$57.99

-0.08 (-0.14%)

18:57
08/15/18
08/15
18:57
08/15/18
18:57
Periodicals
PNC faces subpoenas over low-income housing tax credits, Bloomberg says »

PNC Financial (PNC) has…

PNC

PNC Financial

$142.03

-0.7 (-0.49%)

WFC

Wells Fargo

$57.99

-0.08 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

  • 12

    Apr

  • 13

    Jul

  • 15

    Oct

UTX

United Technologies

$131.75

-0.65 (-0.49%)

18:57
08/15/18
08/15
18:57
08/15/18
18:57
Initiation
United Technologies initiated at UBS »

United Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

B

Barnes Group

$65.59

-0.26 (-0.39%)

18:56
08/15/18
08/15
18:56
08/15/18
18:56
Initiation
Barnes Group initiated at UBS »

Barnes Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.